Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

March 13, 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the promise of GnRH antagonists in prostate cancer.

March 09, 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.

March 05, 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

March 02, 2018

Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.

February 27, 2018

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.

February 27, 2018

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the combination of ibrutinib (Imbruvica) plus nivolumab (Opdivo) in non-Hodgkin lymphoma.

February 23, 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the difference between GnRH antagonists and GnRH agonists.

February 22, 2018

Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor.

February 17, 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

February 16, 2018

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the necessity of tailored approaches in the treatment of patients with neuroendocrine tumors (NETs).

February 15, 2018

Advanced interventional pulmonology techniques are revolutionizing the diagnosis and treatment of lung cancer.

February 15, 2018

Tiffany A. Traina, MD, discusses her experiences with using neratinib and pertuzumab, and shares her excitement on the direction in which the HER2-positive breast cancer field is moving.

February 12, 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.

February 09, 2018

With the advent of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in melanoma physicians are no longer using BRAF inhibitors alone, but rather in combination with MEK inhibitors due to the improved efficacy.

February 07, 2018

Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the emergence and success of new technologies in the treatment of patients with gastrointestinal (GI) malignancies.

February 06, 2018

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.

February 06, 2018

Treatment with encorafenib and binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

February 05, 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with chimeric antigen receptor (CAR) T-cell therapy.

February 03, 2018

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials and recent approvals that will shape the standard of care in the treatment of patients with neuroendocrine tumors (NETs).

February 03, 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in hepatocellular carcinoma (HCC) could affect the treatment landscape in liver cancer.